Vodis Pharmaceuticals Inc. (CSE:VP, FWB:1JV1) (“Vodis” or the “Company”) announces the appointment of John Bean as a director of the Company effective immediately.
Experienced Cannabis Sector CFO Provides Financial Leadership and Further Strengthens Corporate Governance
Mr. Bean, who will sit as an independent Director, has financial management, capital markets and corporate governance experience in the medical cannabis industries. He is a CPA (BC), CA.
Mr. Bean was the CFO of Aurora Cannabis Inc. (TSX:ACB), a licensed producer of medical cannabis, during its first two years as a public company, when it obtained its licence to grow, became licence to sell, and then received customer revenue.
Mr. Bean has served on the boards of Prescient Mining Corp., which became Aurora Cannabis Inc.; General Fusion Inc.; SyncWave Energy Inc.; TAP Ventures, Inc.; RSI International, BC Technologies Industry Association; Accenture’s CSTaR (Center for Strategic Technology Research); and Bobolink Daycare Society for Deaf Children.
“John is a valuable addition to Vodis’ Board, bringing significant financial and capital markets experience, as we enter a pivotal period in our corporate development,” said Ivan Miliovski, CEO. “His wise counsel will serve our shareholders well, as we execute on our strategic plans.”
“I am delighted to join the Vodis team, and excited to support the Company’s rapid growth” said Mr. Bean. ”
In connection with the above appointment, the Company has granted John Bean an aggregate of 200,000 stock options exercisable at $0.485 per common share for a period of five years expiring on December 20, 2022, subject to all requisite regulatory approvals.
About Vodis Pharmaceuticals Inc.
Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.
While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed Vodis-brand quality standards.
For further information please contact:
Ivan Miliovski, Chief Executive Officer
Vodis Pharmaceuticals Inc.
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B4
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
Click here to connect with Vodis Pharmaceuticals Inc. (CSE:VP,FSE:1JV1) for an Investor Presentation.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).